MARKET

ALT

ALT

Altimmune
NASDAQ
5.80
+0.44
+8.21%
Pre Market: 5.78 -0.02 -0.34% 07:06 05/09 EDT
OPEN
5.50
PREV CLOSE
5.36
HIGH
5.90
LOW
5.25
VOLUME
1.78K
TURNOVER
--
52 WEEK HIGH
11.16
52 WEEK LOW
3.553
MARKET CAP
446.68M
P/E (TTM)
-4.3322
1D
5D
1M
3M
1Y
5Y
1D
Altimmune Announces Presentation Of New Analyses Predicting High Rates of MASH Resolution On Biopsy Following Pemvidutide Treatment At EASL International Liver Congress
Benzinga · 1d ago
ALTIMMUNE TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 13, 2025
Reuters · 3d ago
Weekly Report: what happened at ALT last week (0428-0502)?
Weekly Report · 4d ago
Noteworthy Friday Option Activity: ALT, DUOL, AMD
NASDAQ · 6d ago
What's Going On With Altimmune (ALT) Stock Today?
Benzinga · 6d ago
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
Barchart · 05/01 06:30
Altimmune to Participate in the Citizens Life Sciences Conference
Barchart · 04/30 06:30
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)
TipRanks · 04/29 06:21
More
About ALT
More
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Recently
Symbol
Price
%Change

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.